Eldesoky, A., Elshahat, A., Eskander, M., Fouda, M. (2020). Hypofractionated Whole Breast Radiotherapy with Simultaneous Integrated Boost Following Breast Conservative Surgery for Early Breast Cancer. test, 37(1), 259-270. doi: 10.21608/bmfj.2020.79646
Ahmed Ramadan Eldesoky; Ahmed Elshahat; Mona Eskander; Mona Fouda. "Hypofractionated Whole Breast Radiotherapy with Simultaneous Integrated Boost Following Breast Conservative Surgery for Early Breast Cancer". test, 37, 1, 2020, 259-270. doi: 10.21608/bmfj.2020.79646
Eldesoky, A., Elshahat, A., Eskander, M., Fouda, M. (2020). 'Hypofractionated Whole Breast Radiotherapy with Simultaneous Integrated Boost Following Breast Conservative Surgery for Early Breast Cancer', test, 37(1), pp. 259-270. doi: 10.21608/bmfj.2020.79646
Eldesoky, A., Elshahat, A., Eskander, M., Fouda, M. Hypofractionated Whole Breast Radiotherapy with Simultaneous Integrated Boost Following Breast Conservative Surgery for Early Breast Cancer. test, 2020; 37(1): 259-270. doi: 10.21608/bmfj.2020.79646

Hypofractionated Whole Breast Radiotherapy with Simultaneous Integrated Boost Following Breast Conservative Surgery for Early Breast Cancer

Benha Medical Journal
Article 10, Volume 37, Issue 1, May 2020, Pages 259-270    PDF (889.46 K)
Document Type: Original Article
DOI: 10.21608/bmfj.2020.79646
Authors
Ahmed Ramadan Eldesoky1; Ahmed Elshahat2; Mona Eskander2; Mona Fouda2
1Clinical Oncology and Nuclear Medicine Department, Mansoura University, Mansoura, Egypt
2Department of Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Mansoura University Egypt
Abstract
Background: Hypofractionated whole breast radiotherapy (HFWBRT) showed comparable efficacy and safety to conventional fractionated radiotherapy. Dose and fractionation of the tumor bed boost to be integrated during HF-WBRT schedules is still to be determined. Aim: to investigate the clinical feasibility of HF-WBRT with simultaneous integrated boost (SIB), in early breast cancer patients who underwent breast conserving surgery (BCS). Methods: This single arm prospective study included 40 female patients with pathologically proven stage I-II breast cancer following BCS with high risk factors. Patients received 3D conformal radiotherapy (3DCRT) with field in field (FIF) technique. The whole breast received a dose of 40 gray (Gy) over 15 fractions for 3 weeks with an additional SIB dose of 8 Gy over 15 fractions to be give  daily during WBRT. Radiation toxicities were graded using the common terminology criteria for adverse events (NCI-CTCAE) scale version 4.03. Cosmetic outcome was assessed using Harvard cosmetic score. Kaplan Meier method was used to estimate the 3- year disease free (DFS) and overall survival (OS). Results: The median age at presentation was 48 years (range 33-68). No reported grade 3 or 4 toxicities. Grade 1 and 2 radiation dermatitis affected 80% of the patients, breast pain was observed in 62.5% of the patients while 25% had radiation pneumonitis. Most of the patients (95%) had excellent and good cosmetic outcomes. At 3 years the estimated DFS was 95% and OS was 97.5 %. Conclusion: WBRT-SIB using 3DCRT with FIF technique is clinically feasible for early stage breast cancer patients.
Statistics
Article View: 390
PDF Download: 725